UPDATE 1-U.S. extends review of Roche MS drug Ocrevus by three months

ZURICH, Dec 20 (Reuters) - The U.S. Food and Drug

Administration (FDA) has extended its review of Roche's

multiple sclerosis (MS) drug Ocrevus by three months to March

28, the Swiss drugmaker said...

Read more